NCT07324577 Effectiveness of Virtual Reality (VR) in the Management of Anxiety for Patients Undergoing Radiotherapy
| NCT ID | NCT07324577 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Radiation Therapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2026-05-07 |
| Primary Completion | 2029-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 54 participants in total. It began in 2026-05-07 with a primary completion date of 2029-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the use and functionality of virtual reality (VR) during radiation therapy treatments for patients with prostate, breast, lung, or head and neck cancer.
Eligibility Criteria
Patients: Inclusion Criteria: * Participants planned for radiation therapy for 15 or more treatments with non-neutron generating energies (10 MV or less) per study PI for prostate, breast, lung, or head and neck cancer. Neutrons have the potential to damage the VR headset device and are generated for energies above 10 MV. * Age 18 years or older at the time of consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 at the time of enrollment. * Ability to understand and the willingness to sign an IRB-approved informed consent document directly. Exclusion Criteria: * Previous radiation therapy * VR device is determined to impede the radiation dosage during the VR device simulation and treatment planning * Participants with primary brain tumors, brain metastases, and cancer involving the sinuses, orbits, nose, or ears, are excluded from this clinical trial because the VR device may obstruct the area being treated * Participants with uncontrolled inter-current illness including but not limited to psychiatric illness/social situations that would limit compliance with study requirements per treating radiation oncologist. * Participants with known epilepsy, significant motion sickness, severe uncorrected visual impairment, severe uncorrected hearing impairment, or seizures, per participant report. * Participants with skin defects, infections, or open wounds in the area where the VR device is applied (face or scalp) or in the eyes per treating radiation oncologist. * Participants with pacemakers, internal defibrillators, hearing aid, or other implanted medical device. The Meta Quest device contains magnets and components that emit magnetic/electromagnetic fields which could affect the operation of nearby electronics and medical devices. Radiation Therapists: Inclusion Criteria: * Agreement to participate after reviewing the information sheet * Radiation therapist at AHWFBCCC High Point who has treated at least one participant who enrolled on to the study and used the VR device.
Contact & Investigator
Stephanie Parker, MS
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT07324577 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Radiation Therapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07324577 currently recruiting?
Yes, NCT07324577 is actively recruiting participants. Contact the research team at Sheri.Whittington@Advocatehealth.org for enrollment information.
Where is the NCT07324577 trial being conducted?
This trial is being conducted at High Point, United States.
Who is sponsoring the NCT07324577 clinical trial?
NCT07324577 is sponsored by Wake Forest University Health Sciences. The principal investigator is Stephanie Parker, MS at Wake Forest University Health Sciences. The trial plans to enroll 54 participants.